ReviewTherapeutic advances in infectious disease2013
Management of febrile neutropenia in the era of bacterial resistance.
Review in Therapeutic advances in infectious disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effect of Nigella sativa seed administration on prevention of febrile neutropenia during chemotherapy among children with brain tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Trial
- Fever in Children with Cancer: Pathophysiological Insights Using Blood Transcriptomics.International journal of molecular sciences · 2025Article
- A Population-Based Study of Infectious Diseases Mortality Risk in Patients With Hematologic Malignancies 2000-2020.Cancer medicine · 2025Article
- Assessment value of interleukin-6, procalcitonin, and C-reactive protein early kinetics for initial antibiotic efficacy in patients with febrile neutropenia: A prospective study.Cancer medicine · 2024Article
- Article
- Article
- Immature platelet fraction predicts early marrow recovery after severe chemotherapy associated neutropenia.Scientific reports · 2023Article
- Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Febrile neutropenia management and outcomes in hematopoietic cell transplantation for chronic granulomatous disease.Transplant infectious disease : an official journal of the Transplantation Society · 2022Article
- Update on Febrile Neutropenia in Pediatric Oncological Patients Undergoing Chemotherapy.Children (Basel, Switzerland) · 2021Review
- Re-thinking treatment strategies for febrile neutropenia in paediatric oncology population: the perspective from a developing country.Infectious agents and cancer · 2021Article
- Epidemiology of Febrile Neutropenia Episodes with Gram-Negative Bacteria Infection in Patients Who Have Undergone Chemotherapy for Hematologic Malignancies: A Retrospective Study of 10 Years' Data from a Single Center.Infection and drug resistance · 2020Article
- Risk factors for bacteremia in children with febrile neutropeniaTurkish journal of medical sciences · 2019Article
- Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study.Infection · 2019Article
- Management and Preventive Measures for Febrile Neutropenia.P & T : a peer-reviewed journal for formulary management · 2018Article
- Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation.Mediterranean journal of hematology and infectious diseases · 2017Review
- Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.Advances in therapy · 2015Article
- Bacterial Spectrum, Isolation Sites and Susceptibility Patterns of Pathogens in Adult Febrile Neutropenic Cancer Patients at a Specialist Hospital in Saudi Arabia.World journal of oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing cancer patients with fever and neutropenia must be considered as a medical emergency since any delay in initiating appropriate empirical antibacterial therapy may result in high rates of mortality and morbidity. Emerging antibacterial resistance in bacterial pathogens infecting febrile neutropenic patients complicates management, and choosing the type of empirical antimicrobial therapy has become a challenge. To further complicate the decision process, not all neutropenic patients are in same category of susceptibility to develop severe infection. While low-risk patients may be treated with oral antibiotics in the outpatient setting, high-risk patients usually need to be admitted to hospital and receive parenteral broad-spectrum antibiotics until the neutrophil levels recover. These strategies have recently been addressed in two international guidelines from the Infectious Diseases Society of America (IDSA) and the European Conference on Infections in Leukaemia (ECIL). This review gives a brief overview of current antimicrobial resistance problems and their effects in febrile neutropenic cancer patients by summarizing the suggestions from the IDSA and ECIL guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.